KLE Academy of Higher Education and Research (Deemed-to-be-University)
J N Medical College, Belgaum, Karnataka, India
Department of Respiratory Medicine

Research Projects 

Ongoing

Sl NoPrincipal InvestigatorCo-Principal InvestigatorTitle of the ProjectFunding Agency Duration  (From-To) Clinical Trial Registration Details  if anyStatus
1Dr. Jyothi Hattiholi    –A Phase 3 , Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI13506 in Participants with Symptomatic Chronic Obstructive Pulmonary Diseas (COPD) with a History of COPD Exacerbations (OBERON)AstraZeneca – –on going
2Dr. Jyothi Hattiholi    –A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicentre 24 to 52 Week Veriable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meterd Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)AstraZeneca – –on going
3Dr. Jyothi Hattiholi    –Prospective, multi-centre, open-label, single-arm, clinical study to evaluate safety and efficacy of OmaliRelTM in patients with moderate to severe persistent asthma.Reliance Life Sciences – –on going
4Dr. Jyothi Hattiholi    –Randomized double – Blind , Placebo Controlled , parallel-group Phase
III study to evaluate the safety and tolerability of
SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with
moderate-to-severe chronic Obstructive Pulmonary Disease (COPD)
Sanofi – –on going
5Dr. Jyothi Hattiholi    –A Phase III, multicentre, randomised, double-blind, chronic dosing, parallel group, placebo controlled extensions. Study to evaluate the long term efficacy and safety of Tozorakimab in participants with Chronic Obstructive Pulmonary Disease (COPD) with a history of exacerbations ( PROSPERO)AstraZeneca – –on going
6Dr Gautam S    –A Phase 3, multicenter, randomized, double-blind, 24-week study
of the clinical and antiviral effect of S-217622 compared with
placebo in non-hospitalized participants with COVID-19
Shionogi – –on going
7Dr. Jyothi Hattiholi Protocol Title A Randomized, Single-dose, Double-blind, Double-dummy, Placebo and Active Controlled, Crossover Design Study Using Bronchoprovocation to Evaluate the Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma.Intech Biopharm Ltd. – –on going
8Dr. Jyothi Hattiholi Reference: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm
Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2).
Bellus health Inc – –on going

 

International – Completed

Sl NoPrincipal InvestigatorCo-Principal InvestigatorTitle of the ProjectFunding Agency Duration  (From-To) Clinical Trial Registration Details  if anyStatus
1Dr. M.V.Jali, Dr. Vinay Mahishale Bidirectional screening of diabetes Mellitus and tuberculosis

1) Govt of India. 

2) WHO. 3) WDF.

4) International Union against Tuberculsosis and lung diseases.

Jan 2012 to Sept 2012Completed

 

Industry Sponsored Clinical Trials – Completed

Sl NoPrincipal InvestigatorCo-Principal InvestigatorTitle of the ProjectFunding Agency Duration  (From-To) Clinical Trial Registration Details  if anyStatus
1Dr. Vinay Mahishale Roflimulast in COPD

Glenmark

Jan 2013 to June 2013Completed

 

Completed

Sl NoResearch ScholarGuideCo-GuideTitle of the Thesis Duration  (From-To) 
1Dr. Renu PattenshettyDr. G. S. Gaude Effect of multimodality chest physiotherapy on the rate recovery and prevention of complications in patients with mechanical ventilation – a prospective study in medical and surgical intensive care units.2007-2008
2Dr. Ravi SaudattiDr. G. S. Gaude Comparative study of  postural correction and respiratory muscle training, and only respiratory muscle training in patients with chronic obstructive pulmonary diseases.2007-2008